Rocket Pharmaceuticals Reports Positive Safety Update

RCKT Rocket Pharmaceuticals announces positive clinical safety update from initial three patients treated with rp-a501 under modified phase 2 protocol for danon disease Rocket Pharmaceuticals - rp-a501 well-tolerated in initial three patients with no tma or capillary leak syndrome - Engaging with FDA on pivotal trial; regulatory update expected in h2 2026 - Danon disease program update expected in h2 2026